Evidence map›Paper›PMID 35693092›Full record

ArticleAmerican journal of cancer research2022

Oral administration of TRAIL-inducing small molecule ONC201/TIC10 prevents intestinal polyposis in the

Venkateshwar Madka, Arielle De La Cruz, Gopal Pathuri, Janani Panneerselvam, Yuting Zhang, Nicole Stratton, Sean Hacking, Niklas K Finnberg, Howard P Safran, Shizuko Sei and 6 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Venkateshwar MadkaCenter for Cancer Prevention and Drug Development, Hem-Onc Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK, USA.
Arielle De La CruzDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School RI, USA.
Gopal PathuriCenter for Cancer Prevention and Drug Development, Hem-Onc Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK, USA.
Janani PanneerselvamCenter for Cancer Prevention and Drug Development, Hem-Onc Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK, USA.
Yuting ZhangCenter for Cancer Prevention and Drug Development, Hem-Onc Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK, USA.
Nicole StrattonCenter for Cancer Prevention and Drug Development, Hem-Onc Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK, USA.
Sean HackingDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School RI, USA.
Niklas K FinnbergFox Chase Cancer Center Philadelphia, PA, USA.
Howard P SafranHematology/Oncology Division, Warren Alpert Medical School RI, USA.
Shizuko SeiDivision of Cancer Prevention, Chemopreventive Agent Development Research Group, National Cancer Institute Rockville, MD, USA.
Elizabeth R GlazeDivision of Cancer Prevention, Chemopreventive Agent Development Research Group, National Cancer Institute Rockville, MD, USA.
Robert ShoemakerDivision of Cancer Prevention, Chemopreventive Agent Development Research Group, National Cancer Institute Rockville, MD, USA.
Jennifer T FoxDivision of Cancer Prevention, Chemopreventive Agent Development Research Group, National Cancer Institute Rockville, MD, USA.
Alexander G RaufiHematology/Oncology Division, Warren Alpert Medical School RI, USA.
Wafik S El-DeiryDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School RI, USA.
Chinthalapally V RaoCenter for Cancer Prevention and Drug Development, Hem-Onc Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK, USA.
Fox Chase Cancer Center · US

Funding

TIC10 anti-tumor effect through regulation of Foxo3a and TRAILR01CA173453 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI EL-DEIRY, WAFIK S. · 2013 to 2023
$4.3M
NCI NIH HHS HHSN261201500038CNCI NIH HHS R01 CA173453
6 · The paper itself

Abstract

Colorectal cancer (CRC) incidence is rising globally. Hence, preventing this disease is a high priority. With this aim, we determined the CRC prevention potential of the TRAIL-inducing small molecule ONC201/TIC10 using a preclinical model representing high-risk familial adenomatous polyposis (FAP) patients,

Indexed as

chemopreventionColon cancercolon polypFAPmin mouseONC201TIC10TRAIL

Identifiers

PMID35693092
PMCPMC9185612
OpenAlexW4285739765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.